Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.

Pharmacogenetics and genomics - 1 Nov 2006

Blesa Rafael, Bullock Roger, He Yunsheng, Bergman Howard, Gambina Giuseppe, Meyer Joanne, Rapatz Günter, Nagel Jennifer, Lane Roger

Abstract excerpt

A randomized double-blind trial evaluated the efficacy and tolerability of rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), and donepezil, an AChE-selective inhibitor, in patients with Alzheimer's disease over a 2-year period. A retrospective analysis s...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alzheimer Disease
Share to Butyrylcholinesterase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholinesterase Inhibitors

Share to Heterozygote

Share to Indans

Share to Piperidines

Share to Treatment Outcome

Source

Identifiers

PMID: 17047484
DOI: 10.1097/01.fpc.0000220573.05714.ac

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17047484-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.PMID 17047484Read ↗

Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.Semantic proximity Read ↗

Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.Semantic proximity Read ↗

BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.Semantic proximity Read ↗

Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.Semantic proximity Read ↗

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.Semantic proximity Read ↗

Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.Semantic proximity Read ↗

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.Semantic proximity Read ↗

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.Semantic proximity Read ↗

Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.Semantic proximity Read ↗

Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.Semantic proximity Read ↗

Apolipoprotein E genotype and gender influence response to tacrine therapy.Semantic proximity Read ↗

Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer’s Disease—Could BCHE Genotyping Be Helpful in Alzheimer’s Therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.